Breaking News Instant updates and real-time market news.

SSNLF

Samsung

, BIIB

Biogen

$323.66

-0.39 (-0.12%)

07:50
09/15/17
09/15
07:50
09/15/17
07:50

Samsung Bioepis receives positive CHMP opinion on trastuzumab biosimilar

Samsung Bioepis (SSNLF, BIIB) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion on ONTRUZANT, a biosimilar candidate referencing Herceptin, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. The CHMP's positive opinion will now be referred to the European Commission which will decide on the grant of a marketing authorization for ONTRUZANT. If a marketing authorization is granted by the EC, ONTRUZANT will be commercialized in the European Union by Merck (MRK). The Fly notes that Herceptin is a registered trademark of Genentech (RHHBY).

SSNLF

Samsung

BIIB

Biogen

$323.66

-0.39 (-0.12%)

RHHBY

Roche

$31.60

0.11 (0.35%)

MRK

Merck

$66.12

1.14 (1.75%)

  • 22

    Sep

  • 30

    Nov

SSNLF Samsung

05/17/17
MSCO
05/17/17
NO CHANGE
Target $177
MSCO
Overweight
Apple target raised to $177 at Morgan Stanley after survey shows rising loyalty
Morgan Stanley analyst Katy Huberty reported that the firm's recent survey of 1,000 U.S. consumers shows a rising iPhone retention rate, with 92% of iPhone owners who see upgrading their phone in the next 12 months saying they plan to stick to an iPhone, up from the 86% retention rate in last year's survey. Apple's (AAPL) 92% loyalty rate "dwarfs" that of all other vendors, with its biggest competitor, Samsung (SSNLF), seeing a 77% retention rate, she noted. Huberty, who sees Apple being positioned to gain increasing U.S. smartphone share, raised her price target on Apple to $177 from $161 and keeps an Overweight rating on the stock.
09/14/17
KEYB
09/14/17
NO CHANGE
KEYB
Lack of Band 71 inclusion a near-term negative for T-Mobile, says KeyBanc
KeyBanc analyst Brandon Nispel says that the lack of inclusion of band 71, or 600 MHz spectrum, in iconic device launches from Samsung (SSNLF) and Apple (AAPL) is a clear negative for T-Mobile (TMUS). T-Mobile spent $8B to purchase this spectrum and will spend more capital going forward to build it out, without having the ability to put it to use for at least another year, he notes. Nispel believes investors are likely to view this as negative, and it could cause some weakness to shares.
09/13/17
STFL
09/13/17
NO CHANGE
STFL
Buy
Foldable smartphones another potential catalyst for Coherent, says Stifel
Stifel analyst Patrick Newton noted that AP reported yesterday that the President of Samsung's (SSNLF) mobile business said the company could release its anticipated foldable smartphone as soon as next year. Such a potential launch, and likely broader adoption of the technology by peers, is a potential long-term catalyst for Coherent (COHR) and other such equipment suppliers whose revenues are linearly correlated with total screen area, he tells investors. Also, higher resolution OLED displays, like the one confirmed yesterday for Apple's (AAPL) iPhone X, are a positive for Coherent's future recurring revenue from laser discharge units, added Newton, who keeps a Buy rating on Coherent shares.
08/22/17
OPCO
08/22/17
NO CHANGE
Target $35
OPCO
Underperform
Synaptics price target lowered to $35 from $45 at Oppenheimer
Oppenheimer analyst Andrew Uerkwitz lowered his price target for Synaptics (SYNA) to $35 from $45, citing his bearish outlook on the company's fingerprint and DDIC business. The analyst's model implies "significant" fingerprint revenue loss from Samsung (SSNLF) and ongoing decline of DDIC revenues from Apple (AAPL). Meanwhile, Uerkwitz believes its new products such as optical fingerprint sensor and OLED DDIC are unlikely to offset the decline until after FY19. He reiterates an Underperform rating on Synaptics' shares.
BIIB Biogen
$323.66

-0.39 (-0.12%)

08/23/17
WBLR
08/23/17
INITIATION
Target $107
WBLR
Outperform
AveXis initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started AveXis (AVXS) with an Outperform rating and $107 fair value estimate, noting that the company's Phase I data for AVXS-101have continued to show a meaningful benefit in spinal muscular atrophy type 1. The analyst, who thinks AveXis has a high probability of receiving guidance for a potential regulatory filing following the company's end-of-Phase I meeting with the FDA, said AveXis could become an acquisition target within the next 12-18 months. If so, an acquisition price could be in the range of $150-$160 per share, with Roche (RHHBY) and Biogen (BIIB) possible suitors, Prasad tells investors.
08/16/17
08/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Home Depot (HD) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying the company continues to execute at a "world-class level." 2. Mylan (MYL) upgraded to Buy from Neutral at Citi with analyst Liav Abraham saying the company is best positioned to execute in a challenging operating environment for generics. 3. Biogen (BIIB) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Terence Flynn saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. 4. Zions Bancorp (ZION) upgraded to Buy from Neutral at BofA/Merrill with analyst Erika Najarian saying she believes investors are discounting two catalysts for earnings upside including benefits from regulatory reform for regionals and continued improvement in expense management. 5. Paychex (PAYX) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Danyal Hussain saying expectations adequately capture downside risks and the valuation premium is the lowest since 2008. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
GSCO
08/16/17
UPGRADE
Target $338
GSCO
Conviction Buy
Biogen upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Terence Flynn added Biogen to the Conviction Buy List and maintained a $338 price target saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. He expects Phase 3 data in Q4 2019/Q1 2020 saying it could be the first disease modifying drugs on the market with a peak sales estimated at $12B. Further, the analyst views MS competition concerns as overdone and said the balance sheet is relatively under-levered.
09/14/17
RBCM
09/14/17
INITIATION
Target $319
RBCM
Sector Perform
Biogen initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Biogen with a Sector Perform rating and $319 price target.
RHHBY Roche
$31.60

0.11 (0.35%)

08/08/17
JEFF
08/08/17
NO CHANGE
Target $75
JEFF
Buy
FibroGen price target raised to $75 from $50 at Jefferies
Jefferies analyst Michael Yee raised his price target for FibroGen (FGEN) shares to $75 saying "significant value creation should occur now" after the company reported positive Phase II idiopathic pulmonary fibrosis lung data for FG-3019. The analyst believes the $5B market capitalization implied by his new price target could prove conservative. InterMune had comparable data and was acquired by Roche (RHHBY) for $8B, Yee tells investors in a research note. The analyst reiterates a Buy rating on FibroGen. The stock in premarket trading is up 59%, or $19.60, to $53.00.
09/12/17
COWN
09/12/17
NO CHANGE
COWN
Cowen says cervical cancer recommendations a risk for Hologic, Becton Dickinson
Cowen analyst Doug Schenkel noted that the US Preventive Services Task Force recently released a draft recommendation on cervical cancer screening, which no longer recommends cotesting with both an HPV assay and cytology, which would be a negative for Hologic (HOLX) and Becton Dickinson (BDX) if the draft is implemented. If the draft is implemented, it is likely a positive for Roche (RHHBY), the only vendor with a primary screening HPV assay that is FDA approved, added Schenkel. However, the final recommendation statement can be materially different from the draft, he said.
09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
MRK Merck
$66.12

1.14 (1.75%)

09/11/17
BMOC
09/11/17
NO CHANGE
BMOC
Incyte trial result 'assures commercial success,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says the results of a trial of Incyte's (INCY) epacadostat, its selective IDO1 enzyme inhibitor, in combination with Merck's (MRK) Keytruda, in patients with advanced melanoma eliminates the risk of an upcoming Phase 3 trial of epacadostat and "assures its commercial success." The analyst adds, however, that "the bar continues to be raised for IO combinations," which may make it difficult for Incyte's stock to rise in the near-term. The analyst trimmed his price target on the shares to $163 from $172 to reflect the company's capital raise. But he keeps an Outperform rating on the stock.
09/11/17
STFL
09/11/17
NO CHANGE
Target $29
STFL
Buy
NewLink Genetics price target raised to $29 from $14 at Stifel
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.

TODAY'S FREE FLY STORIES

HUBS

HubSpot

$72.15

-1.75 (-2.37%)

17:47
09/26/17
09/26
17:47
09/26/17
17:47
Earnings
HubSpot raises Q3 EPS view to (4c)-(2c) from (10c)-(8c), consensus (9c) »

Raises Q3 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

CSCO

Cisco

$33.76

0.04 (0.12%)

17:46
09/26/17
09/26
17:46
09/26/17
17:46
Periodicals
Cisco to cut around 310 headquarters jobs, Bloomberg reports »

Cisco is cutting about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

HUBS

HubSpot

$72.15

-1.75 (-2.37%)

17:45
09/26/17
09/26
17:45
09/26/17
17:45
Hot Stocks
Breaking Hot Stocks news story on HubSpot 

HubSpot raises Q3 outlook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

NKE

Nike

$53.70

0.47 (0.88%)

17:42
09/26/17
09/26
17:42
09/26/17
17:42
Earnings
Nike sees FY18 revenue growth in mid-single digit range, consensus $36.01B »

Sees FY18 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

NKE

Nike

17:41
09/26/17
09/26
17:41
09/26/17
17:41
Earnings
Nike sees Q2 revenue growth in low single digit range, consensus $8.48B »

Sees Q2 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

LLNW

Limelight Networks

$3.80

0.01 (0.26%)

17:36
09/26/17
09/26
17:36
09/26/17
17:36
Conference/Events
Limelight Networks management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 18

    Oct

  • 14

    Nov

  • 15

    Nov

CTAS

Cintas

$136.10

-0.77 (-0.56%)

, MU

Micron

$34.18

-0.69 (-1.98%)

17:35
09/26/17
09/26
17:35
09/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Cintas…

CTAS

Cintas

$136.10

-0.77 (-0.56%)

MU

Micron

$34.18

-0.69 (-1.98%)

EDIT

Editas Medicine

$20.30

-0.83 (-3.93%)

TWTR

Twitter

$16.59

-0.39 (-2.30%)

NKE

Nike

$53.70

0.47 (0.88%)

KRNT

Kornit Digital

$17.15

-0.15 (-0.87%)

WLKP

Westlake Chemical Partners

$24.10

0.15 (0.63%)

ITCI

Intra-Cellular

$19.23

-0.57 (-2.88%)

ASND

Ascendis Pharma

$37.10

0.97 (2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

NKE

Nike

$53.70

0.47 (0.88%)

17:31
09/26/17
09/26
17:31
09/26/17
17:31
Hot Stocks
Nike: North America marketplace still undergoing 'significant' transformation »

Says seeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

BVXV

BiondVax

17:29
09/26/17
09/26
17:29
09/26/17
17:29
Hot Stocks
Breaking Hot Stocks news story on BiondVax »

Eastern Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$53.70

0.47 (0.88%)

17:23
09/26/17
09/26
17:23
09/26/17
17:23
Hot Stocks
Nike 'bullish' on long-term opportunity in North America. »

Says sportswear category…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

OIS

Oil States

$25.75

0.25 (0.98%)

, STL

Sterling Bancorp

$24.10

0.15 (0.63%)

17:22
09/26/17
09/26
17:22
09/26/17
17:22
Hot Stocks
Breaking Hot Stocks news story on Oil States, Sterling Bancorp »

Oil States to replace…

OIS

Oil States

$25.75

0.25 (0.98%)

STL

Sterling Bancorp

$24.10

0.15 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$16.59

-0.39 (-2.30%)

17:21
09/26/17
09/26
17:21
09/26/17
17:21
Hot Stocks
Twitter to begin testing longer 280 character Tweets with small group »

Aliza Rosen, product…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

, AF

Astoria Financial

$21.09

0.08 (0.38%)

17:21
09/26/17
09/26
17:21
09/26/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Kemet, Astoria Financial »

Kemet to replace Astoria…

KEM

Kemet

AF

Astoria Financial

$21.09

0.08 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

STL

Sterling Bancorp

$24.10

0.15 (0.63%)

, OIS

Oil States

$25.75

0.25 (0.98%)

17:20
09/26/17
09/26
17:20
09/26/17
17:20
Hot Stocks
Sterling Bancorp to repalce Oil States in S&P 400 at open on 10/2 »

Sterling Bancorp (STL) …

STL

Sterling Bancorp

$24.10

0.15 (0.63%)

OIS

Oil States

$25.75

0.25 (0.98%)

AF

Astoria Financial

$21.09

0.08 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$16.59

-0.39 (-2.30%)

17:20
09/26/17
09/26
17:20
09/26/17
17:20
Hot Stocks
Twitter jumps after announcing testing for longer Tweets »

Shares of Twitter are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.02

0.25 (0.43%)

, PRXL

Parexel

$88.05

0.035 (0.04%)

17:18
09/26/17
09/26
17:18
09/26/17
17:18
Hot Stocks
Six Flags to replace Parexel in S&P 400 at open on 10/2 »

Pamplona Capital…

SIX

Six Flags

$58.02

0.25 (0.43%)

PRXL

Parexel

$88.05

0.035 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

NKE

Nike

17:16
09/26/17
09/26
17:16
09/26/17
17:16
Hot Stocks
Nike says Q1 online sales up 19% »

Says Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

HOMB

Home Bancshares

$24.05

0.28 (1.18%)

, SGBK

Stonegate Bank

$51.62

0.59 (1.16%)

17:11
09/26/17
09/26
17:11
09/26/17
17:11
Hot Stocks
Home Bancshares announces completion of the acquisition of Stonegate Bank »

Home BancShares (HOMB)…

HOMB

Home Bancshares

$24.05

0.28 (1.18%)

SGBK

Stonegate Bank

$51.62

0.59 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

TWTR

Twitter

$16.59

-0.39 (-2.30%)

17:11
09/26/17
09/26
17:11
09/26/17
17:11
Hot Stocks
Twitter to begin testing longer 280 character tweets with small group »

Aliza Rosen, product…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMH

American Homes 4 Rent

$22.03

0.04 (0.18%)

17:08
09/26/17
09/26
17:08
09/26/17
17:08
Hot Stocks
American Homes 4 Rent estimates to pay $10M in damage from recent hurricanes »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.03

0.14 (0.22%)

17:05
09/26/17
09/26
17:05
09/26/17
17:05
Hot Stocks
T-Mobile to acquire remaining interest of iWireless from Aureon »

T-Mobile US announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ZSAN

Zosano Pharma

$0.79

-0.0498 (-5.93%)

17:04
09/26/17
09/26
17:04
09/26/17
17:04
Hot Stocks
Zosano Pharma provides patent application update »

Zosano Pharma received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELUXY

Electrolux AB

$69.63

-0.2675 (-0.38%)

17:02
09/26/17
09/26
17:02
09/26/17
17:02
Downgrade
Electrolux AB rating change  »

Electrolux AB downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$284.74

3.37 (1.20%)

17:01
09/26/17
09/26
17:01
09/26/17
17:01
Hot Stocks
Northrop Grumman COO Flach to retire, Warden named next COO »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBB

Westbury Bancorp

$20.05

-0.3508 (-1.72%)

17:00
09/26/17
09/26
17:00
09/26/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Westbury Bancorp  »

Westbury Bancorp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.